Doctors and medical researchers met during the International Conference on Malignant Lymphoma to discuss potential approaches to treating patients with rare cancers as well as refractory or relapsed disease.

Dr Thomas Mehrling, CEO of EDO (Mundipharma EDO GmbH), explained that as a fledgling company, EDO aims to turn new concepts in cancer therapy into clinical reality as efficiently as possible.

Tinostamustine (EDO-S101) is EDO’s first molecule to enter clinical studies and researchers shared their endeavours from bench to bedside.

Scientific exchange is key to finding new targets to treat difficult cancers.
New molecules and gene profiling are steps to unlocking potential benefit for conditions where patient survival is poor with current therapies.

Although tinostamustine (EDO-S101) is only in Phase 1, this first-in-class AK-DAC (alkylating deacetylase inhibiting molecule) has shown a low IC$_{50}$ preclinically and appears to overcome some of today's resistance barriers.

Antibody drug conjugates are another early stage proposition from EDO with its focus firmly on finding ‘smart cancer therapies’ for the future.
Researchers connecting with clinicians may focus attention on patients' unmet needs.

Clinical trials have started in haematological tumours, but are planned to extend to solid tumours based on features identified during tinostamustine’s (EDO-S101) preclinical investigations.

EDO hopes to be able to impact upon patients current unmet needs, which is why its primary focus is on those types of cancer with limited treatment options.

For more information, please contact info@edoncology.com